AACR: Study Shows PD-L1 Expression Can ID Best Responders to Merck's anti-PD-1 Immunotherapy in NSCLC | GenomeWeb

PHILADELPHIA – Non-small cell lung cancer patients who had PD-L1 expression in at least half of their tumor cells saw their tumors shrink in greater numbers and lived longer after treatment with Merck's Keytruda (pembrolizumab) than patients with lower levels of expression, researchers reported yesterday at the American Association for Cancer Research annual meeting.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.